Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 4/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5368869 | 0.90 | KDM4E (0.47) | KDM4ERAB9APPARGPPARAPOLB | |
| SCHEMBL3530493 | 0.89 | RAB9A (0.53) | KDM4ERAB9APPARGPPARAPOLB | |
| SCHEMBL6511253 | 0.88 | KDM4E (0.60) | KDM4ERAB9APPARGPPARAPOLB | |
| SCHEMBL27589269 | 0.87 | KDM4E (0.46) | KDM4ERAB9APPARGPPARASMN1; SMN2 | |
| SCHEMBL820945 | 0.86 | SMN1; SMN2 (0.51) | KDM4ERAB9APPARGPPARAPOLB | |
| SCHEMBL18095717 | 0.85 | PPARG (0.46) | KDM4ERAB9APPARGPPARAPOLB | |
| SCHEMBL4888378 | 0.83 | RAB9A (0.62) | KDM4ERAB9APPARGPPARALMNA | |
| SCHEMBL1436051 | 0.83 | PPARA (0.51) | KDM4ERAB9APPARGPPARAMAPT | |
| SCHEMBL1436227 | 0.83 | HSD17B10 (0.54) | KDM4ERAB9APPARGPPARAPOLB | |
| SCHEMBL1981068 | 0.83 | PPARG (0.54) | KDM4ERAB9APPARGPPARAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054309-A9 | METHODS OF IDENTIFYING AND TREATING PATIENTS HAVING NEURODEGENERATIVE DISEASE BASED ON PLASMA BIOMARKER LEVELS | T3D THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250099434-A1 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| WO-2025054309-A1 | METHODS OF IDENTIFYING AND TREATING PATIENTS HAVING NEURODEGENERATIVE DISEASE BASED ON PLASMA BIOMARKER LEVELS | T3D THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025024308-A1 | METHODS OF TREATING ENDOTHELIAL CELL AND AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146818-A2 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | T3D THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | T3D THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | T3D THERAPEUTICS INC (US) | 2021-12-02 | — | — | US | disclosed |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | DARA BIOSCIENCES, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20180117013-A1 | METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180117013-A1 | METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180117013-A1 | METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3273964-A1 | METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES | T3D Therapeutics Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016154258-A1 | METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016154258-A1 | METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| US-7241784-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-10 | — | — | US | disclosed |
| US-20040087636-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-05-06 | — | — | US | disclosed |
| US-6664281-B1 | Oxazol-4-yl-alkoxy- or alkthioxy- functionality; peroxisome proliferator activated receptor regulators | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| EP-1108713-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180117013-A1 | METHODS OF TREATING LIVER DISEASE USING INDANE ACETIC ACID DERIVATIVES | ACAT2, ACAT1, CPT1A | KDM4E 4152/4885RAB9A 3568/4885PPARG 14/4885 |
| US-20040087636-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | PPARA, PPARG, PPARD | KDM4E 2833/4885RAB9A 3543/4885PPARG 2/4885 |
| US-20210212996-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES USING INDANE ACETIC ACID DERIVATIVES WHICH PENETRATE THE BLOOD BRAIN BARRIER | PPARG, PPARA, PPARD | KDM4E 4568/4885RAB9A 1945/4885PPARG 1/4885 |
| US-20210369680-A1 | METHODS OF TREATING DISEASES AND DISORDERS RESULTING FROM BETA CORONAVIRUS INFECTION | PPARD, PPARA, PPARG | KDM4E 4710/4885RAB9A 2055/4885PPARG 3/4885 |
| US-20250099434-A1 | METHODS OF TREATING AMYLOID RELATED BRAIN DISORDERS USING NOVEL COMPOUNDS AND ANTIBODIES | MAPT, APP, IAPP | KDM4E 4250/4885RAB9A 2869/4885PPARG 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.